Evidence map›Paper›PMID 41743727›Full record

ReviewFrontiers in immunology2026

ADAR1: a central regulator of dsRNA sensing in host-virus interactions.

Congnuan Liu, Younho Choi

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Congnuan LiuFlorida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, United States.
Younho ChoiFlorida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenosine deaminase acting on RNA 1 (ADAR1) is a key regulator of RNA homeostasis and innate immunity through its adenosine-to-inosine (A-to-I) editing of double-stranded RNAs (dsRNAs). By editing endogenous dsRNAs, ADAR1 prevents inappropriate activation of RNA sensors such as PKR, RIG-I, and MDA5, thereby maintaining immune tolerance to self RNA. However, growing evidence indicates that this essential immunomodulatory function of ADAR1 can be exploited by viruses to facilitate infection. Many viruses leverage ADAR1 to suppress RLR- and PKR-mediated signaling, dampen type I interferon responses, and promote viral replication-highlighting a prominent proviral role for ADAR1. Conversely, ADAR1 can also exert antiviral effects, including hyper-editing of viral genomes, disruption of viral RNA structures, and modulation of host antiviral signaling pathways. Thus, ADAR1 acts as a context-dependent regulator of virus-host interactions, functioning both as a guardian against aberrant immune activation and as a host factor co-opted by viruses to establish productive infection. Understanding how viruses manipulate ADAR1 and how ADAR1 differentially impacts PKR and RIG-I/MDA5 pathways will advance our knowledge of viral immune evasion mechanisms and may inform new therapeutic strategies. This review summarizes current insights into the antiviral and proviral roles of ADAR1 during viral infection, with emphasis on viral strategies that finetune ADAR1 activity to shape infection outcomes.

Indexed as

ADAR1A-to-I editinghost-virus interactionPKRRNA sensing pathways

Identifiers

PMID41743727
PMCPMC12929370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.